Jazz Pharmaceuticals plc JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. 10-K, Item 1
- Employees
- 2,890
- Headquarters
- Dublin
- CEO
- Renee D. Gala
- Next results
- around Jan 11, 2027
JAZZ among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
23 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 24, 2026 against Feb 26, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Receivables growing faster than revenueReceivables +15.9% ($716.8M to $830.7M) vs revenue +4.9% ($4.1B to $4.3B), +11.0 pts apart
-
Cash from operations $1.4B vs net income −$356.1M (FY ending Dec 31, 2025)
9 more checks with nothing to note
-
Inventory -13.2% ($480.4M to $417.0M) vs revenue +4.9% ($4.1B to $4.3B), -18.1 pts apart
-
Same auditor in both 10-Ks: KPMG
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Assessment of Epidiolex Medicaid Rebate Accrual
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
23 paragraphs in Risk Factors that were not in the 10-K filed Feb 26, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
On July 4, 2025, President Trump signed into law the OBBBA, which includes significant changes to Medicaid, Medicare, and the ACA. These reforms are anticipated to decrease federal health care spending by approximately $1 trillion by significantly reducing Medicaid spending and enrollment, making changes to the Medicare program, and…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
MFN pricing models have remained an area of significant interest to the Trump Administration. On July 31, 2025, President Trump issued letters to 17 pharmaceutical companies reiterating the requirements of the May 12, 2025 executive order and demanding that such companies extend MFN pricing to Medicaid patients, guarantee MFN pricing…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
While we are an Irish company headquartered in Dublin, Ireland, we derive the majority of our revenues from sales of our products in the U.S. We conduct business globally and our operations, including third-party suppliers, span numerous countries outside the U.S. In particular, we have a manufacturing and development facility in…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
On April 21, 2025, we completed the acquisition of all the outstanding shares of Chimerix Common Stock. As a result of this, Chimerix became our indirect wholly owned subsidiary. The success of the acquisition will depend, in part, on our ability to realize the anticipated benefits from successfully combining our and Chimerix’s…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $3.7B | $3.8B | $4.1B | $4.3B |
| Net income | −$224.1M | $414.8M | $560.1M | −$356.1M |
| Operating cash flow | $1.3B | $1.1B | $1.4B | $1.4B |
| Free cash flow | $1.2B | $1.1B | $1.4B | $1.3B |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$4.3B ▲ 4.9% in FY2025−$356.1M in FY2025$1.3B ▼ 4.5% in FY2025
Recent filings
7 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 6, 2026BRUCE COZADD (Director) gave notice of a planned sale of 68,808 shares worth about $16.2M Form 144, approximate sale date Nov 6, 2026
-
Planned saleNov 4, 2026PATRICIA CARR (Officer) gave notice of a planned sale of 1,413 shares worth about $327K Form 144, approximate sale date Nov 4, 2026
-
Planned saleNov 3, 2026RENEE D GALA (Officer, Director) gave notice of a planned sale of 1,000 shares worth about $225K Form 144, approximate sale date Nov 3, 2026, under a 10b5-1 plan adopted Jun 4, 2026
-
Planned saleNov 2, 2026Bruce C Cozadd (Officer) gave notice of a planned sale of 6,000 shares worth about $1.3M Form 144, approximate sale date Nov 2, 2026, under a 10b5-1 plan adopted Nov 26, 2025
-
8-KNov 2, 2026Quarterly results 8-K item 2.02
About the company
Jazz Pharmaceuticals plc, Dublin · from the 10-K filed Feb 24, 2026
Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease - often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering R&D advancements across our robust pipeline of innovative therapeutics.
- Headquarters
- Dublin
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 2, 2026
- Incorporated in
- Ireland
Employees, at the top of the page: "As of December 31, 2025, Jazz employed approximately 2,890 people worldwide, with approximately 53% in the U" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 26, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/JAZZ/export.csv") into a cell.